Trivium Point Advisory’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
Trivium Point Advisory's XBI Position: Q1 2025 in Review
Trivium Point Advisory sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2025, closing a stake of 28,429 shares — an estimated $2.56M sold.
Trivium Point Advisory first reported a position in XBI in Q1 2024 and held it in 4 quarters. The position peaked at $7.3M in Q3 2024. 682 funds tracked by Wall St. Rank hold XBI as of Q1 2025.
- Trivium Point Advisory reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2025 after selling out during the quarter.
- Trivium Point Advisory sold 28,429 State Street SPDR S&P Biotech ETF shares in Q1 2025, an estimated $2.56M.
- Trivium Point Advisory first reported a position in State Street SPDR S&P Biotech ETF in Q1 2024 and held it in 4 quarters.
- Trivium Point Advisory's State Street SPDR S&P Biotech ETF position peaked at $7.3M in Q3 2024.
- 682 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2025.
Based on Trivium Point Advisory's 13F filing for Q1 2025, filed 13 May 2025.